Cochrane Finds Evidence Supporting Nicotine E-Cigarettes for Quitting Smoking

Dec.01.2022
Cochrane Finds Evidence Supporting Nicotine E-Cigarettes for Quitting Smoking
Cochrane finds evidence that nicotine e-cigarettes increase quitting rates, while PSC questions the study's integrity.

An international non-profit healthcare academic group Cochrane has recently released their latest findings on the effectiveness of nicotine e-cigarettes. The study concludes that there is high-confidence evidence suggesting that e-cigarettes containing nicotine can increase smoking cessation rates, and moderate-confidence evidence showing that they can improve cessation rates compared to nicotine-free e-cigarettes.


The conclusions drawn by Cochrane are widely considered to be the gold standard in evidence-based healthcare. As such, the highly credible findings of Cochrane's investigation should encourage regulatory authorities around the world to ensure that adult smokers are legally able to access electronic cigarette products.


In response to the latest research findings from Cochrane, the Physicians for a Smoke-Free Canada (PSC) released a misleading blog questioning the integrity of the Cochrane authors and their conclusions. The PSC ignored the history of electronic cigarette science and promoted information that contradicts the statement released by the Canadian Department of Health regarding the Cochrane findings.


Regarding the use of electronic cigarettes for quitting smoking, the Canadian Department of Health stated that "quitting smoking may be difficult, and electronic cigarettes may offer a way to release nicotine with less harm than smoking tobacco. These products may reduce the health risks for individuals who do not quit smoking nicotine altogether. While there is still controversy surrounding their use, some evidence suggests that using electronic cigarettes is associated with an increased success rate in quitting smoking.


Cynthia Callard is a registered member of the Physicians for a Smoke-Free Canada (PSC) and has written many publications for the organization. According to the PSC's charitable records, 98% of their total revenue comes from the Canadian government. However, none of the government funding has been used to operate smoking cessation clinics, charitable programs, or any other initiatives aimed at reducing the burden of combustible tobacco on public health in Canada.


The PSC has expressed its efforts to implement stricter regulations by the Canadian government in order to reduce the supply and demand of electronic cigarette products. However, the issue with this approach is that while regulations can effectively decrease the supply of legally operated and regulated electronic cigarette products, historically speaking, the impact of regulations on demand is minimal. As a result of past regulatory changes, Canada's illicit electronic cigarette market has grown significantly. Further regulations undoubtedly exacerbate the proliferation of unregulated and potentially dangerous products. The illicit market poses a threat to consumer safety and increases the risks faced by young people. The regulation of electronic cigarette products must ensure that they can be purchased through legal channels to protect consumers' rights.


The electronic cigarette is a tool designed to help adults quit smoking. The Canadian Vaping Association (CVA) supports comments on harm reduction measures. Smoking remains the primary cause of smoking-related diseases in humans. Preventing tobacco-related diseases is still the medical profession's top priority," said Darryl Tempest, CVA committee government relations advisor.


The Canadian Vaping Association (CVA) is a registered national nonprofit organization that serves as an advocate for Canada's vaping industry. Established in 2014, CVA represents over 200 e-cigarette companies in Canada.


2FIRSTS will continue to report on this issue, with updates available on the 2FIRSTS app. Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

How Many Nicotine Pouch Factories Does Europe Need? 2Firsts Interviews AIRSCREAM on the OEM Market
How Many Nicotine Pouch Factories Does Europe Need? 2Firsts Interviews AIRSCREAM on the OEM Market
At InterTabac 2026, nicotine pouch growth was visible not only in brands but across equipment, raw materials and OEM manufacturing. 2Firsts interviewed AIRSCREAM commercial head Steve Moore on how many pouch factories Europe may ultimately need and where manufacturers can differentiate, from formulation and flavour to pouch materials, production consistency and customer service. The category continues to expand, but questions remain over future capacity, consolidation and the long-term structure of the supply chain.
Sep.18
Scottish Vape Display Rules Could Cost Businesses £61 Million, Affecting More Than 11,000 Retail Outlets
Scottish Vape Display Rules Could Cost Businesses £61 Million, Affecting More Than 11,000 Retail Outlets
A Scottish government impact assessment estimates that proposed vape display and packaging rules could create up to £61 million ($82 million) in compliance costs for businesses, affecting more than 11,000 retail outlets. The estimated costs are mainly linked to inventory adjustments, retail storage changes and the resources required for businesses to understand and implement the new requirements. The measures form part of the UK’s broader efforts to tighten vape regulation, particularly around product displays, packaging and sales practices.
Aug.10
Product | BAT Expands VELO Travellers’ Collection With Mexico, Spain and Sweden Summer Edition Nicotine Pouches
Product | BAT Expands VELO Travellers’ Collection With Mexico, Spain and Sweden Summer Edition Nicotine Pouches
British American Tobacco (BAT) Global Travel Retail has expanded the VELO Travellers’ Collection with three new Summer Editions: Mexico, Spain and Sweden. Inspired by destination themes, the new nicotine pouch variants are designed for global travel-retail channels. The launch further strengthens VELO’s positioning as a travel-retail exclusive product collection.
Aug.27
Philippines Customs Seizes PHP11.68 Billion($200 Million) in Illegal Tobacco and Vapes in First Seven Months of 2026
Philippines Customs Seizes PHP11.68 Billion($200 Million) in Illegal Tobacco and Vapes in First Seven Months of 2026
Philippines Customs data showed that illegal cigarettes and vape products seized during the first seven months of 2026 were valued at about PHP11.68 billion, exceeding the PHP2.516 billion recorded for the full year of 2025. The figures were disclosed by a Bureau of Customs official during a House Committee on Ways and Means hearing on tobacco excise tax reforms. Vape-related seizures were valued at about PHP1.65 billion, with most cases recorded at the Manila International Container Port. Customs officials said enforcement against illicit tobacco trade would continue.
Aug.26
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
2Firsts reviewed the original federal court complaint filed by Altria subsidiaries Helix Innovations and NJOY on Sept. 2 challenging FDA’s 2021 PMTA rule. The lawsuit questions whether FDA’s review process complies with the Tobacco Control Act’s 180-day timeline, even as the agency moves to accelerate PMTA reviews and issues more marketing orders. Drawing on the complaint, FDA records, government audits and recent court rulings, 2Firsts examines the legal arguments, supporting evidence and potential implications for the U.S. tobacco review system.
Regulations
Sep.03
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
FDA CTP Director Bret Koplow used his FDLI keynote in Washington to outline how the agency is rethinking the PMTA framework. He discussed category-specific review, nicotine pouch and sPMTA pilots, AI-assisted review, a 70% reduction in pending applications, and a major staffing constraint: CTP currently has only nine scientific review teams. He also reaffirmed tobacco harm reduction while stressing youth protection, flavored products, risk communication, and the challenge of unauthorized e-cigarettes.
Regulations
Oct.06